ScreenerHero

ROVI Laboratorios Farmaceuticos Rovi, S.A.

BME · ES · Healthcare · Drug Manufacturers - Specialty & Generic · rovi.es
57.25EUR-0.61%Mkt Cap: 3.18B $P/E: 15.81

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, B…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation - Common Stock
$23.23BUSDP/E 19.4
VTRS
Viatris Inc. - Common Stock
$20.22BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc. - Common Stock
$14.55BUSDP/E 21.0
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
AMRX
Amneal Pharmaceuticals, Inc. - Class A Common Stock
$7.07BUSDP/E 42.3
ALKS
Alkermes plc - Ordinary Shares
$7.00BUSDP/E 109.9
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc. - Common Stock
$6.53BUSDP/E 23.9
KNSA
Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares
$5.83BUSDP/E 76.6
INDV
Indivior Pharmaceuticals, Inc. - Common Stock
$4.21BUSDP/E 12.8

Key Statistics

Company
Market Cap3.18B USD
Enterprise Value3.19B USD
Revenue (TTM)840.27M USD
Gross Profit524.66M USD
Net Income (TTM)152.65M USD
Revenue/Share15.12 EUR
Last Price57.25 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.5K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINES0157261019
Valuation
P/E (Trailing)15.81
P/E (Forward)17.10
PEG1.26
EV/EBITDA16.66
EV/Revenue3.79
P/S3.80
P/B4.19
EPS (TTM)3.62
EPS (Forward)3.36
52W Range
53.1012% of range86.70
52W High86.70 EUR
52W Low53.10 EUR
Profitability
Gross Margin64.92%
Oper. Margin9.42%
EBITDA Margin22.76%
Profit Margin18.89%
ROE21.14%
ROA14.70%
Growth
Revenue Growth20.00%
Earnings Growth246.70%
Cash Flow & Leverage
Operating CF203.35M USD
CapEx (TTM)73.71M USD
FCF Margin21.67%
FCF Yield5.72%
Net Debt-22.15M USD
Net Debt/EBITDA-0.12
Balance Sheet
Debt/Equity0.18
Current Ratio2.05
Quick Ratio1.04
Book Value/Sh13.70 EUR
Cash/Share2.50 EUR
Dividends
Fwd Div Rate0.96 EUR
Trail. Div Rate0.96 EUR
Div. Yield1.67%
5Y Avg Yield1.38%
Payout Ratio25.83%
Ex-Div DateJul 13, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)74.36 EUR
Upside (mean)+29.9%
Target Range64.20 EUR – 83.00 EUR
64.20+29.9% to mean83.00
# Analysts9
Ownership
Shares Out.51.14M
Float16.20M
Insiders68.20%
Institutions16.58%
Technical
SMA 5058.93 (-2.8%)
SMA 20066.92 (-14.5%)
Beta0.23
S&P 52W Chg14.58%
Avg Vol (30d)59.64K
Avg Vol (10d)90.25K
Technical Indicators
RSI (14)40.8
MACD-0.0759
MACD Signal0.0183
MACD Hist.-0.0941
BB Upper60.27 EUR
BB Middle58.45 EUR
BB Lower56.63 EUR
BB Width6.21%
ATR (14)1.143 EUR
Vol Ratio (20d)1.05x